在上皮卵巢癌中,与化疗耐药性相关的DNA甲基化特征与化疗耐药性有关
Changling Duan1, Zhongxin Yan1, Cailiang Wu1
1Department of Obstetrics and Gynecology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, 200080, Shanghai, China.
Heliyon
|March 12, 2024
概括
DNA甲基化模式,特别是低甲基化CpG,是表皮卵巢癌 (EOC) 中化学抵抗的关键预测因素. 这项研究确定了特定的甲基化位点和基因,如DDR2和OPCML,为EOC治疗耐药性提供了新的见解.
科学领域:
- 在瘤学瘤学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 基因组学就是基因组学.
背景情况:
- 表皮卵巢癌 (EOC) 的死亡率很高,主要是由于获得的化学抵抗.
- DNA甲基化被认为是预测EOC化学抗性的关键生物标志物.
研究的目的:
- 确定与EOC中化学抵抗相关的差异甲基化CpG位点 (DMC) 和基因 (DMG).
- 使用DMCs构建化学抵抗的预测模型.
- 调查DMC,DMG和化学抵抗之间的相关性.
主要方法:
- 使用了来自GEO和TCGA数据库的DNA甲基化概况.
- 在化学耐药和化学敏感的EOC患者之间确定了DMC.
- 开发了基于DMCs的化学抵抗风险模型.
- 通过免疫组织化学分析了候选DMG及其与DMC的相关性.
主要成果:
- 在耐化学性EOC患者中鉴定出423个高甲基化和1445个低甲基化CpG.
- 化学抵抗风险模型显示出预测能力 (AUC 65.0-76.2%).
- 特定的CpG (例如,cg25510164,cg13154880) 与化学抵抗风险降低有关,而其他 (例如,cg08872590) 增加了风险.
- 确定了13种DMG,其中DDR2和OPCML与DMC有很强的相关性,并且在耐化学物质的组织中增强表达.
结论:
- 低甲基化CpG在EOC化学抵抗中发挥着重要作用.
- 像DDR2这样的基因的表观遗传修饰与化学抵抗的发展有关.
- 这项研究为未来关于DNA甲基化和EOC化学抵抗的研究提供了宝贵的见解.
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Epigenetic Regulation
3.0K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
3.0K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K


